Pyxis Oncology (NASDAQ:PYXS) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Pyxis Oncology (NASDAQ:PYXS) from a hold rating to a sell rating in a research report released on Saturday.

PYXS has been the topic of a number of other reports. Stephens lifted their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research report on Monday, November 3rd. They issued a “buy” rating and a $9.00 price target on the stock. HC Wainwright increased their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday. Guggenheim lifted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.20.

Pyxis Oncology Stock Down 26.3%

Shares of NASDAQ:PYXS opened at $1.28 on Friday. The firm has a market cap of $79.38 million, a P/E ratio of -0.80 and a beta of 1.37. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.55. The business has a fifty day simple moving average of $4.01 and a 200 day simple moving average of $2.38.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. As a group, equities research analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Pyxis Oncology in the 1st quarter valued at about $125,000. 683 Capital Management LLC increased its position in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after buying an additional 135,000 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Pyxis Oncology in the 1st quarter valued at about $81,000. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Pyxis Oncology during the 2nd quarter worth approximately $37,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.